2001
Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies
Mao Q, Ray S, Laeyendecker O, Ticehurst J, Strathdee S, Vlahov D, Thomas D. Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies. Journal Of Virology 2001, 75: 3259-3267. PMID: 11238852, PMCID: PMC114119, DOI: 10.1128/jvi.75.7.3259-3267.2001.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHCV quasispeciesHypervariable region 1HIV seroconversionChronic hepatitis C virus (HCV) infectionE2 hypervariable region 1Hepatitis C virus infectionHuman immunodeficiency virus (HIV) seroconversionRapid HIV disease progressionHepatitis C virus quasispeciesHIV infection altersHIV-associated diseaseChronic HCV infectionC virus infectionHIV disease progressionHCV infectionHCV RNASerum levelsLiver diseaseImmunodeficiency virusDisease progressionRapid progressionVirus infectionNumber of subjectsHCV sequences
2000
Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00126334-200004010-00005.Peer-Reviewed Original ResearchHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug useImproved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy.
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved antioxidant status among HIV-infected injecting drug users on potent antiretroviral therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-6. PMID: 10836754, DOI: 10.1097/00126334-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsSerum alpha-tocopherol levelsAlpha-tocopherolPotent antiretroviral therapyAlpha-tocopherol levelsExcess oxidative stressOxidative stress levelsAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceDrug useHIVImproved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy
Tang A, Smit E, Semba R, Shah N, Lyles C, Li D, Vlahov D. Improved Antioxidant Status Among HIV-Infected Injecting Drug Users on Potent Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 23: 321-326. DOI: 10.1097/00042560-200004010-00006.Peer-Reviewed Original ResearchConceptsHIV-positive IDUsHIV-negative IDUsAntiretroviral therapySerum antioxidant levelsLutein/zeaxanthinStudy subjectsART regimenAntioxidant levelsSerum levelsDrug usersProtease inhibitorsLow serum antioxidant levelsPotent antiretroviral therapyInjecting Drug UsersExcess oxidative stressOxidative stress levelsΒ-cryptoxanthinAlcohol intakeSerum antioxidantsDietary intakeAntioxidant statusSignificant overall differenceΑ-tocopherolSerum αDrug use
1997
Persistence and Clinical Significance of Hepatitis G Virus Infections in Injecting Drug Users
Thomas D, Nakatsuji Y, Shih J, Alter H, Nelson K, Astemborski J, Lyles C, Vlahov D. Persistence and Clinical Significance of Hepatitis G Virus Infections in Injecting Drug Users. The Journal Of Infectious Diseases 1997, 176: 586-592. PMID: 9291303, DOI: 10.1086/514078.Peer-Reviewed Original ResearchConceptsHepatitis G virus infectionG virus infectionHGV RNAHGV infectionVirus infectionDrug usersLiver-related enzymesRecent serum sampleInjecting Drug UsersHepatic inflammationAcute infectionSerum levelsLiver diseaseClinical significanceNegative participantsSerial samplesDrug useInfectionPrior visitSerum samplesIDUsPrior specimensRecent visitVisitsYears
1993
Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users
Strickler H, Blanchard J, Vlahov D, Taylor E, Muñoz A, Nelson K, Margolick J. Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users. AIDS 1993, 7: 361-368. PMID: 8471199, DOI: 10.1097/00002030-199303000-00009.Peer-Reviewed Original ResearchConceptsDrug useNeopterin levelsSerum levelsDrug usersSerum beta 2MBeta 2M levelsSerum beta 2M levelsMean neopterin levelsSerum neopterin levelsElevated serum levelsHIV-1 infectionCellular immune activationBeta 2MRisk factor variablesIntravenous Experience (ALIVE) studyM levelsMale IDUsSerum neopterinImmune activationProspective studyImmunocompetent cellsHIV-1Β2-microglobulinConsecutive daysNeopterin